Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study
- 242 Downloads
Subjects who view experimental procedures as worthwhile are more likely to participate in clinical trials and comply with study procedures. Designing studies that consider the consumer’s perspective will help to forge a better alliance between participants and researchers.
Participant satisfaction is seldom assessed in pharmacological research. In this paper, we report on parent satisfaction in a randomized clinical trial in children with autistic disorder and severely disruptive behavior.
Parents of 101 children with autism who had participated in a multi-site 8-week double-blind clinical trial of risperidone were given a questionnaire at the end to elicit their perceptions of the appropriateness and acceptability of clinical trial procedures.
Ninety-six (95.0%) parents returned the questionnaire. Of these, 80.0 to 96.8%, depending on the question, expressed satisfaction with their child’s research participation regardless of treatment outcome or assignment to active drug or placebo. In all, 90.5% of parents indicated that they would “definitely” recommend the clinical trial to other families with similar children. A total of 92.7% indicated that they would rejoin the clinical trial if they had to do it all over again. Ethnic minority subjects were more satisfied than white participants with the use of “learning tests”.
Parents of children participating in this trial were highly satisfied and supportive of the clinical trial procedures. Random assignment to drug or placebo and the clinical response of their children did not appear to influence their views. Further satisfaction studies of this sort are encouraged.
KeywordsAutism Consumer satisfaction Parent satisfaction Clinical trial Child Risperidone
This study was supported by contracts from the National Institute of Mental Health (N01MH70001 to Dr. McDougle, N01MH70009 to Dr. Scahill, N01MH80011 to Dr. Aman, and N01MH70010 to Dr. McCracken), General Clinical Research Center grants from the National Institutes of Health (M01 RR00750 to Indiana University, M01 RR06022 to Yale University, M01 RR00034 to Ohio State University, and M01 RR00052 to Johns Hopkins University), and Korczak Foundation to Dr. Scahill. This experiment complies with the law of the USA of America, in which it was performed.
The opinions and assertions contained in this report are the private views of the authors and are not to be construed as official or as reflecting the views of the National Institute of Mental Health, the National Institutes of Health, or the Department of Health and Human Services.
- APA (American Psychiatric Association) (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Press, Washington, DCGoogle Scholar
- Arnold LE, Aman MG, Martin A, Collier-Crespin A, Vitiello B, Tierney E, Asarnow R, Bell-Bradshaw F, Freeman BJ, Gates-Ulanet P, Klin A, McCracken JT, McDougle CJ, McGough JJ, Posey DJ, Scahill L, Swiezy NB, Ritz L, Volkmar F (2000) Assessment in multisite randomized clinical trials (RCTs) of patients with autistic disorder: the autism RUPP network. J Autism Dev Disord 30:99–111PubMedCrossRefGoogle Scholar
- Guy W (1976) Clinical global impressions scale. ECDEU assessment: manual for psychopharmacology (revised edition). US Dept of Health, Education & Welfare. US Dept of Health, Education & Welfare publication (ADM 76–338), Rockville, MD, pp 217–222Google Scholar
- Kazdin AE (1977) Assessing the clinical or applied importance of behavior change through social validation. Behav Modif 1:427–452Google Scholar
- McAdam DB, Zarcone JR, Hellings J, Napolitano DA, Schroeder SR (2002) Effects of risperidone on aberrant behavior in persons with developmental disabilities: II. social validity measures. AAMR 107:261–269Google Scholar
- McDougle CJ, Scahill L, McCracken JT, Aman MG, Tierney E, Arnold LE, Freeman BJ, Martin A, McGough JJ, Cronin P, Posey DJ, Riddle MA, Ritz L, Swiezy NB, Vitiello B, Volkmar FR, Votolato NA, Walson P (2000) Research units on pediatric psychopharmacology (RUPP)–autism network: background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am 9(1):201–224PubMedGoogle Scholar
- Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabino GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD (2001) Once-a-day concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107(6):E105PubMedCrossRefGoogle Scholar
- Scahill L, McCracken JT, McDougle CJ, Aman MG, Arnold LE, Tierney E, Cronin P, Davies M, Ghuman J, Gonzalez N, Koenig K, Lindsay R, Martin A, McGough J, Posey DJ, Swiezy N, Volkmar F, Ritz L, Vitiello B (2001) Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. J Child Adolesc Psychopharmacol 11(4):377–388PubMedCrossRefGoogle Scholar
- Scahill L, McDougle CJ, William SK, Dimitropoulos A, Aman MG, McCracken J, Tierney E, Arnold LE, Cronin P, Grados M, Ghuman J, Koenig K, Langworthy-Lam K, McGough J, Posey DJ, Ritz L, Swiezy NB, Vitiello B (2006) The children’s Yale-Brown obsessive compulsive scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psych 45:1114CrossRefGoogle Scholar
- Wan GJ, Bukstein O (2003) Satisfaction with once-daily OROS methylphenidate in children and adolescents with ADHD. Poster presented at 16th US Psychiatric Mental Health Congress, Orlando, Florida, November 6–9Google Scholar
- Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, August G, Greenhill L, McBurnett K, Palumbo D, Swanson J, Wolraich M (2003) ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psych 42(4):424–433Google Scholar